Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3953)	1/17/1998 12:56:00 AM
From: Vector1	Read Replies (1) \| Respond to of 9719

<<(2) you lose ten good opportunities while researching a single "past stinker". In this age of excellent science mixed with business, why bother?>> In my day job (the one that pays the mortgage) I have made a sucessful career out of investing in down and out companies that no one else wanted to look at. In many cases these were manufacturing companies that had suffered from lack of investment or poor management. Biotechs are different. The assets lie in the skill and knowledge of the key employees and these folks who are in high demand and rarely stay in failing companies. The more I look at down and out biotechs the more I conclude that there is good reason for their failure. Unfortunately, old habbits are hard to break, especially when they worked in the past. Thus I will probably continue to be attracted to research some down and out names in the hope of finding a bargain. Thanks for your comments. V1